Founded in 1993
  Year: 2008 | Volume: 16 | Issue: 3-4 | Pages: 42-45
  Review Article
  FULLERENOL - A NEW NANOPHARMACEUTIC?
Aleksandar Šordevic, Gordana Bogdanovic
  DOI: 10.2298/AOO0804042D
  Abstract:
  Chemical modification of fullerenes to hydrosoluble cluster molecules made fullerenes interesting for biological investigation. Among them, polycarbonated and polyhydroxylated fullerene C60 derivatives showed the most interesting biological activities. In this paper, we present the most important recent results of in vitro and in vivo biological studies with fullerenol C60(OH)24. Fullerenol C60(OH)24 was strong antioxidant: it reacted with superoxide anion radical, hydroxy radical and nitrous oxide radical in chemical and biological systems. Fullerenol C60(OH)24 did not inhibit human breast cancer cell growth at concentrations from 0.8 to 3.45 mM, but strongly modulated cytotoxic effects of doxorubicin and cis-platinum after 24 and 48 hours of treatment. Radioprotective effects of fullerenol C60(OH)24 were shown in different in vitro and in vivo models. Fullerenol C60(OH)24 (100 mg/kg) protected rat heart from doxorubicin toxicity. Biodistribution studies of fulelrenol were also investigated. Accumulating data from the literature and from our studies suggest that fullerenol, as a nanoparticle might be a new promising pharmaceutical in the near future.
  Key words: Fulleren; Antioxidants; Doxorubicin; Drug Toxicity; Protective Agents; Radiation-Protective Agents
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:
 

  Related articles in AoO:
 
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520